Literature DB >> 16210624

Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin.

Dubravka Grdic1, Lena Ekman, Karin Schön, Kristina Lindgren, Johan Mattsson, Karl-Eric Magnusson, Paola Ricciardi-Castagnoli, Nils Lycke.   

Abstract

The in vivo mechanisms of action of most vaccine adjuvants are poorly understood. In this study, we present data in mice that reveal a series of critical interactions between the cholera toxin (CT) adjuvant and the dendritic cells (DC) of the splenic marginal zone (MZ) that lead to effective priming of an immune response. For the first time, we have followed adjuvant targeting of MZ DC in vivo. We used CT-conjugated OVA and found that the Ag selectively accumulated in MZ DC following i.v. injections. The uptake of Ag into DC was GM1 ganglioside receptor dependent and mediated by the B subunit of CT (CTB). The targeted MZ DC were quite unique in their phenotype: CD11c(+), CD8alpha(-), CD11b(-), B220(-), and expressing intermediate or low levels of MHC class II and DEC205. Whereas CTB only delivered the Ag to MZ DC, the ADP-ribosyltransferase activity of CT was required for the maturation and migration of DC to the T cell zone, where these cells distinctly up-regulated CD86, but not CD80. This interaction appeared to instruct Ag-specific CD4(+) T cells to move into the B cell follicle and strongly support germinal center formations. These events may explain why CT-conjugated Ag is substantially more immunogenic than Ag admixed with soluble CT and why CTB-conjugated Ag can tolerize immune responses when given orally or at other mucosal sites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210624     DOI: 10.4049/jimmunol.175.8.5192

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Cholera toxin adjuvant promotes a balanced Th1/Th2/Th17 response independently of IL-12 and IL-17 by acting on Gsα in CD11b⁺ DCs.

Authors:  J Mattsson; K Schön; L Ekman; L Fahlén-Yrlid; U Yrlid; N Y Lycke
Journal:  Mucosal Immunol       Date:  2014-11-26       Impact factor: 7.313

2.  Cholera toxin subunit B peptide fusion proteins reveal impaired oral tolerance induction in diabetes-prone but not in diabetes-resistant mice.

Authors:  Maximiliano Presa; Angela Zarama Ortiz; Nahir Garabatos; Cristina Izquierdo; Elisa I Rivas; Luc Teyton; Conchi Mora; David Serreze; Thomas Stratmann
Journal:  Eur J Immunol       Date:  2013-08-27       Impact factor: 5.532

3.  Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.

Authors:  Praveen Alamuri; Kathryn A Eaton; Stephanie D Himpsl; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2008-11-24       Impact factor: 3.441

4.  Low doses of cholera toxin and its mediator cAMP induce CTLA-2 secretion by dendritic cells to enhance regulatory T cell conversion.

Authors:  Cinthia Silva-Vilches; Katrien Pletinckx; Miriam Lohnert; Vladimir Pavlovic; Diyaaeldin Ashour; Vini John; Emilia Vendelova; Susanne Kneitz; Jie Zhou; Rena Chen; Thomas Reinheckel; Thomas D Mueller; Jochen Bodem; Manfred B Lutz
Journal:  PLoS One       Date:  2017-07-31       Impact factor: 3.240

Review 5.  Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.

Authors:  Terry D Connell
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.